[submit_job_form]
Recent Posts
- Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform May 8, 2023
- Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update March 30, 2023
- Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement March 2, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com